Form 4: Director Christopher Christie Receives Equity Grant

Pacira BioSciences director Christopher Christie was granted 6,405 restricted stock units and 10,891 stock options.

Summary

• Director Christopher Christie acquired 6,405 restricted stock units (RSUs) on June 10, 2026.
• The director was also granted 10,891 stock options with an exercise price of $23.42.
• Both the RSUs and the stock options are subject to a one-year vesting period, becoming exercisable on June 10, 2027.
• Following these transactions, the director's total direct beneficial ownership of common stock increased to 23,059 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of board leadership through standard vesting schedules.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Vesting is contingent upon the director remaining in continuous service with the issuer.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term performance goals.

Comparison to Industry Standards

• The use of one-year cliff vesting for director equity is consistent with standard practices for mid-cap biotechnology companies.
• The grant size is typical for board-level compensation packages in the pharmaceutical industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on June 10, 2027.

Key Dates

Keywords

Pacira BioSciences, PCRX, Form 4, Insider Trading, Equity Compensation, Director Ownership